Hypoxia represents one of the key factors that stimulates the growth of leukemic cells in their niche. Leukemic cells in hypoxic conditions are forced to reprogram their original transcriptome, miRNome, and metabolome. How the coupling of microRNAs (miRNAs)/mRNAs helps to maintain or progress the leukemic status is still not fully described. MiRNAs regulate practically all biological processes within cells and play a crucial role in the development/progression of leukemia. In the present study, we aimed to uncover the impact of hsa-miR-155-5p (miR-155, MIR155HG) on the metabolism, proliferation, and mRNA/miRNA network of human chronic lymphocytic leukemia cells (CLL) in hypoxic conditions. As a model of CLL, we used the human MEC-1 cell line where we deleted mature miR-155 with CRISPR/Cas9. We determined that miR-155 deficiency in leukemic MEC-1 cells results in lower proliferation even in hypoxic conditions in comparison to MEC-1 control cells. Additionally, in MEC-1 miR-155 deficient cells we observed decreased number of populations of cells in S phase. The miR-155 deficiency under hypoxic conditions was accompanied by an increased apoptosis. We detected a stimulatory effect of miR-155 deficiency and hypoxia at the level of gene expression, seen in significant overexpression of EGLN1, GLUT1, GLUT3 in MEC-1 miR-155 deficient cells. MiR-155 deficiency and hypoxia resulted in increase of glucose and lactate uptake. Pyruvate, ETC and ATP were reduced. To conclude, miR-155 deficiency and hypoxia affects glucose and lactate metabolism by stimulating the expression of glucose transporters as GLUT1, GLUT3, and EGLN1 [Hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2)] genes in the MEC-1 cells.

Center for Advanced Preclinical Imaging 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Molecular Biotechnology and Health Sciences University of Torino and Division of Hematology A O U Città Della Salute E Della Scienza Di Torino Torino Italy

Institute Biocev 1st Faculty of Medicine Charles University Vestec Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Oncological Pharmacology Laboratory Department of Oncology University of Torino Torino Italy

Zobrazit více v PubMed

Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci. 2021 doi: 10.3390/ijms22115703. PubMed DOI PMC

Gacche RN, Assaraf YG. Redundant angiogenic signaling and tumor drug resistance. Drug Resist Updat. 2018;36:47–76. doi: 10.1016/j.drup.2018.01.002. PubMed DOI

Godet I, Shin YJ, Ju JA, Ye IC, Wang G, Gilkes DM. Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis. Nat Commun. 2019;10:4862. doi: 10.1038/s41467-019-12412-1. PubMed DOI PMC

Koczula KM, Ludwig C, Hayden R, Cronin L, Pratt G, Parry H, Tennant D, Drayson M, Bunce CM, Khanim FL, et al. Metabolic plasticity in CLL: adaptation to the hypoxic niche. Leukemia. 2016;30:65–73. doi: 10.1038/leu.2015.187. PubMed DOI PMC

Xie H, Simon MC. Oxygen availability and metabolic reprogramming in cancer. J Biol Chem. 2017;292:16825–16832. doi: 10.1074/jbc.R117.799973. PubMed DOI PMC

Pliszka M, Szablewski L. Glucose transporters as a target for anticancer therapy. Cancers. 2021 doi: 10.3390/cancers13164184. PubMed DOI PMC

Wright EM. Glucose transport families SLC5 and SLC50. Mol Asp Med. 2013;34:183–196. doi: 10.1016/j.mam.2012.11.002. PubMed DOI

Long W, Panwar P, Witkowska K, Wong K, O'Neill D, Chen XZ, Lemieux MJ, Cheeseman CI. Critical roles of two hydrophobic residues within human glucose transporter 9 (hSLC2A9) in substrate selectivity and urate transport. J Biol Chem. 2015;290:15292–15303. doi: 10.1074/jbc.M114.611178. PubMed DOI PMC

Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, Hricak H, Klimstra D, Fong Y. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771–775. doi: 10.2967/jnumed.106.037291. PubMed DOI

Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016;65:124–139. doi: 10.1016/j.metabol.2015.10.007. PubMed DOI

Heydarzadeh S, Moshtaghie AA, Daneshpoor M, Hedayati M. Regulators of glucose uptake in thyroid cancer cell lines. Cell Commun Signal. 2020;18:83. doi: 10.1186/s12964-020-00586-x. PubMed DOI PMC

Taefehshokr S, Taefehshokr N, Hemmat N, Hajazimian S, Isazadeh A, Dadebighlu P, Baradaran B. The pivotal role of MicroRNAs in glucose metabolism in cancer. Pathol Res Pract. 2021;217:153314. doi: 10.1016/j.prp.2020.153314. PubMed DOI

Kim S, Lee E, Jung J, Lee JW, Kim HJ, Kim J, Yoo HJ, Lee HJ, Chae SY, Jeon SM, et al. microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer. Oncogene. 2018;37:2982–2991. doi: 10.1038/s41388-018-0124-4. PubMed DOI PMC

Li X, Yang Y, Zhang B, Lin X, Fu X, An Y, Zou Y, Wang J-X, Wang Z, Yu T. Lactate metabolism in human health and disease. Signal Transduct Target Ther. 2022;7:305. doi: 10.1038/s41392-022-01151-3. PubMed DOI PMC

Pedroza-Torres A, Romero-Córdoba SL, Justo-Garrido M, Salido-Guadarrama I, Rodríguez-Bautista R, Montaño S, Muñiz-Mendoza R, Arriaga-Canon C, Fragoso-Ontiveros V, Álvarez-Gómez RM, et al. MicroRNAs in tumor cell metabolism: roles and therapeutic opportunities. Front Oncol. 2019;9:1404. doi: 10.3389/fonc.2019.01404. PubMed DOI PMC

Sawai S, Wong P-F, Ramasamy TS. Hypoxia-regulated microRNAs: the molecular drivers of tumor progression. Crit Rev Biochem Mol Biol. 2022;57:351–376. doi: 10.1080/10409238.2022.2088684. PubMed DOI

Moszyńska A, Jaśkiewicz M, Serocki M, Cabaj A, Crossman DK, Bartoszewska S, Gebert M, Dąbrowski M, Collawn JF, Bartoszewski R. The hypoxia-induced changes in miRNA-mRNA in RNA-induced silencing complexes and HIF-2 induced miRNAs in human endothelial cells. FASEB J. 2022;36:e22412. doi: 10.1096/fj.202101987R. PubMed DOI PMC

Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 2009;1792:497–505. doi: 10.1016/j.bbadis.2009.02.013. PubMed DOI

Elton TS, Selemon H, Elton SM, Parinandi NL. Regulation of the MIR155 host gene in physiological and pathological processes. Gene. 2013;532:1–12. doi: 10.1016/j.gene.2012.12.009. PubMed DOI

Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122:1891–1899. doi: 10.1182/blood-2013-01-478222. PubMed DOI PMC

Vargova K, Pesta M, Obrtlikova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, et al. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J. 2017;7:e585. doi: 10.1038/bcj.2017.63. PubMed DOI PMC

Tang L, Peng Y-Z, Li C-G, Jiang H-W, Mei H, Hu Y. Prognostic and clinicopathological significance of MiR-155 in hematologic malignancies: a systematic review and meta-analysis. J Cancer. 2019;10:654–664. doi: 10.7150/jca.28537. PubMed DOI PMC

Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu C-G, Calin GA, Croce CM, Chan DA, Giaccia AJ, et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009;113:5568–5574. doi: 10.1182/blood-2008-10-185686. PubMed DOI PMC

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Bo MD, Magliulo D, Rossi D, et al. HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica. 2020;105:1042–1054. doi: 10.3324/haematol.2019.217430. PubMed DOI PMC

Kontos CK, Papageorgiou SG, Diamantopoulos MA, Scorilas A, Bazani E, Vasilatou D, Gkontopoulos K, Glezou E, Stavroulaki G, Dimitriadis G, et al. mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): an independent predictor of poor overall survival in chronic lymphocytic leukemia. Leuk Res. 2017;53:65–73. doi: 10.1016/j.leukres.2016.11.014. PubMed DOI

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Wibom R, Hagenfeldt L, von Döbeln U. Measurement of ATP production and respiratory chain enzyme activities in mitochondria isolated from small muscle biopsy samples. Anal Biochem. 2002;311:139–151. doi: 10.1016/s0003-2697(02)00424-4. PubMed DOI

Sebestyén A, Kopper L, Dankó T, Tímár J. Hypoxia signaling in cancer: from basics to clinical practice. Pathol Oncol Res. 2021;27:1609802. doi: 10.3389/pore.2021.1609802. PubMed DOI PMC

Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21:268–283. doi: 10.1038/s41580-020-0227-y. PubMed DOI PMC

Burrows N, Maxwell PH. Hypoxia and B cells. Exp Cell Res. 2017;356:197–203. doi: 10.1016/j.yexcr.2017.03.019. PubMed DOI

Hanna BS, Öztürk S, Seiffert M. Beyond bystanders: myeloid cells in chronic lymphocytic leukemia. Mol Immunol. 2019;110:77–87. doi: 10.1016/j.molimm.2017.11.014. PubMed DOI

Seiffert M. HIF-1α: a potential treatment target in chronic lymphocytic leukemia. Haematologica. 2020;105:856–858. doi: 10.3324/haematol.2019.246330. PubMed DOI PMC

Adhi Pangarsa E, Rizky D, Setiawan B, Santosa D, Mubarika Haryana S, Suharti C. Crosstalk between hypoxia and inflammation in non-Hodgkin lymphoma. Bali Med J. 2022;11:1063–1073. doi: 10.15562/bmj.v11i3.3491. DOI

Rinderknecht H, Ehnert S, Braun B, Histing T, Nussler AK, Linnemann C. The art of inducing hypoxia. Oxygen. 2021;1:46–61. doi: 10.3390/oxygen1010006. DOI

Guo M, Song L-P, Jiang Y, Liu W, Yu Y, Chen GQ. Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1alpha independent mechanisms. Apoptosis. 2006;11:67–77. doi: 10.1007/s10495-005-3085-3. PubMed DOI

Hubbi ME, Gilkes DM, Hu H, Kshitiz; Ahmed I., Semenza G.L. Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression. Proc Natl Acad Sci U S A. 2014;111:E3325–E3334. doi: 10.1073/pnas.1412840111. PubMed DOI PMC

Huang H-Y, Lin Y-C-D, Cui S, Huang Y, Tang Y, Xu J, Bao J, Li Y, Wen J, Zuo H, et al. miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions. Nucl Acid Res. 2022;50:D222–D230. doi: 10.1093/nar/gkab1079. PubMed DOI PMC

Panuzzo C, Pironi L, Maglione A, Rocco S, Stanga S, Riganti C, Kopecka J, Shahzad Ali M, Pergolizzi B, Bracco E, Cilloni D. mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells. Int J Mol Sci. 2023;24(2):1234. doi: 10.3390/ijms24021234. PubMed DOI PMC

Koh M-Y, Powis G. Passing the baton: the HIF switch. Trend Biochem Sci. 2012;37(9):364–372. doi: 10.1016/j.tibs.2012.06.004. PubMed DOI PMC

Mircea I, Kaelin WG, Jr. The EGLN1-HIF O2-sensing system: multiple inputs and feedbacks. Mol Cell. 2017;66(6):772–779. doi: 10.1016/j.molcel.2017.06.002. PubMed DOI PMC

Mechanism of Action of circRNA/miRNA Network in DLBCL